Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) EPIGENOMICS AG ANNOUNCES CAPITAL INCREASE

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro   adhoc with the aim of a Europe-wide distribution. The issuer is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Company Information/Molecular diagnostics

08.03.2010

Not for distribution in the United States

Berlin, Germany, March 08, 2010 - Today the Executive Board of Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96), with the approval of the Supervisory Board, resolved to increase the issued share capital from EUR 29,394,724.00 by up to EUR 14,697,361.00 up to EUR 44,092,085.00 by issuing up to 14,697,361 new ordinary bearer shares with no- par value, each such share representing a notional nominal amount of the issued share capital of EUR 1.00 per share against cash contributions utilizing authorized capital.

The new shares will be offered to the Company's shareholders at a ratio of 2:1 (existing shares with subscription rights:new shares) for subscription at a subscription price of EUR 2.25 per new share. ICF Kursmakler AG, Frankfurt am Main, Germany, represented by Bankhaus Gebr. Martin AG, Göppingen, Germany, will, subject to certain conditions, act as subscription agent towards shareholders who wish to exercise their subscriptions rights. The subscription offer is expected to be published in the Frankfurter Allgemeine Zeitung, Amtsblatt zur Wiener Zeitung as well as on the Company's website (www.epigenomics.de) and in the electronic German Federal Gazette (elektronischer Bundesanzeiger) on March 12, 2010. The subscription period for the Company's shareholders is expected to begin on March 15, 2010 and to end on March 29, 2010 (in each case including such dates). The new shares carry full dividend rights as from January 1, 2009. The subscription rights of two existing shares are excluded pursuant to Section 71b of the German Stock Corporation Act (Aktiengesetz).

New shares that are not subscribed for in the subscription offer by existing shareholders will be offered by ICF Kursmakler AG (i) in a public offering in Germany and Austria, (ii) to selected institutional investors in Europe, (iii) to qualified institutional buyers in the U.S. in compliance with the exemption from the registration requirements provided by Rule 144A under the U.S. Securities Act of 1933, as amended, or in accordance with another exemption under the U.S. Securities Act of 1933, as amended, and (iv) in offshore transactions in reliance on Regulation S under the U.S. Securities Act of 1933, as amended, except for Canada, Australia and Japan.

Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to build and strengthen the marketing, sales, and distribution capacities for its products, to support ongoing and new product development for its business in cancer screening, diagnosis, disease progression and recurrence monitoring, and assessment of disease prognosis and in this areas in particular the funding of further R&D, clinical trials, regulatory approvals and market introduction of its products that are currently in its product pipeline as well as enhancing and strengthening capabilities related to regulatory affairs and clinical trials, further improvement of the DNA methylation technology, additional in-licensing agreements and strengthening its intellectual property portfolio, as well as for general corporate purposes.

Disclaimer

This publication is not an offer of any securities for sale  or  a   solicitation of an offer to purchase any securities. Any offer of shares will  only  be  made by and on the basis of a prospectus to be published.

This document is not an offer of securities for sale or  a   solicitation  of  an offer to purchase securities in the United States. The shares of Epigenomics  AG (the "Shares") have not been registered under the U.S. Securities Act  of  1933, as amended (the "Securities Act") and may not be offered or sold in  the  United States unless registered under the Securities Act or pursuant  to  an exemption from such registration. There will be no public offering of the  Shares  in  the United States and the Shares will not be registered under the Securities Act.

This document is only being distributed to and is only directed at   (i)  persons who are outside the United Kingdom or (ii) to investment professionals  falling within Article 19(5) of the Financial Services and Markets Act  2000  (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and  other persons to  whom  it   may  lawfully  be  communicated,  falling  within  Article 49(2)(a) to (d) of the Order (all such persons together  being  referred  to   as "relevant persons"). The Shares are  only  available  to,  and   any  invitation, offer or agreement to subscribe, purchase or otherwise acquire  such  securities will be engaged in only  with,   relevant  persons.  Any  person  who  is  not  a relevant person should not act or rely on this document or any of its contents.

This communication expressly  or  implicitly  contains  certain   forward-looking statements concerning Epigenomics AG and its business. Such  statements  involve certain known and unknown risks, uncertainties and  other  factors  which  could cause the actual results, financial condition, performance  or  achievements  of Epigenomics AG to be materially different from any future  results,   performance or  achievements  expressed  or  implied  by  such   forward-looking  statements. Epigenomics AG is providing this communication as of  this  date  and  does  not undertake to update any forward-looking statements contained herein as a  result of new information, future events or otherwise.

Contact:

Epigenomics AG Dr. Achim Plum Senior VP Corporate Development Kleine Präsidentenstr. 1 10178 Berlin Germany +49 30 24345 368 (phone) +49 30 24345 555 (fax) achim.plum@epigenomics.com

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN:      DE000A0BVT96
WKN:        A0BVT9
Index:    Prime All Share, Technology All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              München / free trade



Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: